This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Cancer Drug Stocks to Know Right Now

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Aveo Pharmaceuticals (AVEO)

ASCO presentation: Full presentation of results from the phase III study of tivozanib in kidney cancer.

What we already know: Top-line results from the kidney cancer study were announced in early January with tivozanib demonstrating a progression-free survival of 11.9 months compared to 9.1 months for Nexavar. In a subset of treatment-naive patients, tivozanib PFS was 12.7 months.

Key questions: Nexavar performed better than expected in the study, which narrowed the benefit shown by tivozanib and caused some investors to question the tivozanib's true efficacy. Aveo asserts tivozanib's safety data (to be fully disclosed at ASCO) demonstrates superiority over Nexavar.
6 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $6.38 -0.47%
ARRY $3.98 0.51%
CLDX $17.57 -2.40%
JNJ $102.19 0.94%
ONTY $3.43 -3.40%


Chart of I:DJI
DOW 17,820.24 +100.32 0.57%
S&P 500 2,092.06 +11.65 0.56%
NASDAQ 5,131.4460 +22.78 0.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs